ProBioGen and ImmunOs Therapeutics have extended their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs’ biologic.

“We at ImmunOs are very satisfied with the work done by ProBioGen,” said Jeff Abbey, chief operating officer of ImmunOs Therapeutics. “We highly appreciate the collaborative partnership with ProBioGen and the team’s dedication and solution orientation. The tireless effort of the ProBioGen team has enabled ImmunOs to start clinical development as planned and to meet our milestones.”

René Brecht, chief operations officer of ProBioGen said, “Partnership is one of our core values, as it is key in working successfully together. With this in mind we are confident that our continuous collaboration is based on mutual trust and reliability.”